Can-Fite To Initiate Phase I/II Hepatitis C Trial

Can-Fite is going to initiate phase I/II clinical trial with CF102 for the treatment of Hepatitis C Virus (HCV), following the approval by the Israel Ministry of Health and Rabin MC Ethics Committee.

The trial would investigate the safety and efficacy of CF102 in patients with HCV, and would include 32 patients. The enrollment of the patients has already been initiated, said the company.

The company recently announced the successful completion of a phase I clinical study with CF102 under an IND in the US, showing a safety profile and a linear pharmacokinetic behavior of the drug.

Pnina Fishman, CEO of Can-Fite, said: The initiation of the Phase I/II trial in HCV demonstrates the progress of the company in its clinical development program. Based on the definitive molecular mechanism of CF102 which targets the highly specific enzyme NS5 in the viral replication cycle, we have a great belief in the performance of the drug.”